Mary Kay Inc. Names Wendy Wang President for the Asia Pacific Region
11.3.2021 05:11:00 EET | Business Wire | Press release
Global beauty brand Mary Kay Inc., a leading corporate advocate of women’s entrepreneurship and empowerment, with its global headquarters in Addison, Texas, U.S.A, recently announced the appointment of Wendy Wang as President of its Asia Pacific Region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210310005138/en/
Wendy Wang, President of Mary Kay’s Asia Pacific Region (Photo: Mary Kay Inc.)
In her new role, Wang will provide strategic vision and leadership while working to create growth for the Company in the Asia Pacific region and beyond. Wang joined Mary Kay’s Corporate Legal Department in 2002 as Counsel for the Asia Pacific region. Shortly thereafter, she began a multi-year assignment in China. Upon her return to the global corporate headquarters in 2012, she was promoted to the position of Vice President and Associate General Counsel where she was responsible for legal work and compliance in all four regions. In 2019, Wang returned to China for a new assignment and was promoted to the position of Chief Commercial Officer for the Asia Pacific Region in 2020. In this role, she developed and drove the implementation of commercial strategies, and lead the Asia Pacific regional team in support of sales, marketing, business technology and operations, preparing her to take on the challenge of the Region President responsibilities.
“We want to congratulate Wendy as she transitions into her new role as President of Mary Kay Asia Pacific,” said David Holl, Mary Kay Chairman and Chief Executive Officer. “Wendy is passionate for the Mary Kay independent sales force and is a proven leader within Mary Kay. During her tenure, she has tirelessly built a strong and talented legal team that created a culture of compliance and compassion for China and the entire Asia Pacific Region. We are thrilled to welcome her as a member of the executive committee as we build on our efforts to enrich women’s lives around the globe.”
A graduate of The University of Texas at Austin, Wang earned her law degree as well as an undergraduate degree in Economics. She has received numerous honors and accolades including her recognition in 2017 by D CEO magazine as ‘Outstanding Deputy General Counsel/Associate General’ and the Greater Dallas Asian American Chamber of Commerce ‘Corporate Executive Diversity’ award.
“I am committed to empowering women and their families in the Asia Pacific region,” says Wang. “Supporting Mary Kay’s independent sales force is my greatest honor and always brings me hope, love and confidence in our future. We are a people business with a mission to enrich women’s lives and a vision to empower the Independent Beauty Consultant. My team and I are committed to delivering the very best business opportunity, building upon the values Mary Kay upholds as cornerstones of our corporate culture and mission.”
The promotion of Wang is the latest in Mary Kay Inc.’s decades-long commitment to empowering women to serve in leadership positions around the globe. Mary Kay is a company built by women for women, and that core value is reflected in Mary Kay’s global workforce gender diversity data (as of March 2021):
- 61% of Mary Kay’s global workforce is female
- 59% of Directors and above are female
- 54% of Global Vice Presidents and above are female
- Over 50% of Mary Kay’s global executive team is female
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company nearly 60 years ago with three goals: develop a rewarding opportunity for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay Inc. is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances which are sold exclusively by Mary Kay independent beauty consultants.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005138/en/
Contact information
Mary Kay Inc. Corporate Communications
Marykay.com/newsroom
(+1) 972.687.5332 or media@mkcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom